

*Disclaimer :*

*The Competition DG makes the information provided by the notifying parties in section 1.2 of Form CO available to the public in order to increase transparency. This information has been prepared by the notifying parties under their sole responsibility, and its content in no way prejudices the view the Commission may take of the planned operation. Nor can the Commission be held responsible for any incorrect or misleading information contained therein.*

**M.9461 - ABBVIE / ALLERGAN**

**SECTION 1.2**

**Description of the concentration**

1. On 25 June 2019, AbbVie Inc. (“**AbbVie**”) and Allergan plc (“**Allergan**”) announced that the companies have entered into a transaction agreement under which AbbVie will acquire Allergan in a cash and stock transaction for a transaction equity value of approximately USD 63 billion.
2. AbbVie is a global, research-based biopharmaceutical company engaged in the development and marketing of innovative therapies for the treatment of patients with complex and serious diseases. AbbVie has activities in six main therapeutic areas: immunology, oncology, virology, neurological disorders, metabolic diseases and pain associated with endometriosis. AbbVie is headquartered in North Chicago, Illinois (USA) and is listed on the New York Stock Exchange.
3. Allergan is a global pharmaceutical company engaged in developing, manufacturing and commercialising branded pharmaceutical, device, biologic, surgical and regenerative medicine products for patients globally. Allergan has a marketed and pipeline portfolio of brands and products primarily focused on four key therapeutic areas: medical aesthetics, eye care, central nervous system and gastroenterology. Allergan is headquartered in Dublin (Ireland) and is listed on the New York Stock Exchange.